LianBio Board Unanimously Rejects $4.30/Share Unsolicited Bid from Concentra Biosciences

LianBio

Board unanimously determined not to pursue unsolicited proposal from Concentra Biosciences.
Proposal was $4.30 per share cash plus contingent value right for 80% of net proceeds from license/disposition of programs.
Board concluded proposal undervalues the company and is not in the best interests of shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.